KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Depreciation & Amortization (CF): 2009-2025

Historic Depreciation & Amortization (CF) for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Sep 2025 value amounting to $18.5 million.

  • Biomarin Pharmaceutical's Depreciation & Amortization (CF) fell 2.73% to $18.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.7 million, marking a year-over-year decrease of 17.01%. This contributed to the annual value of $96.4 million for FY2024, which is 7.63% down from last year.
  • Biomarin Pharmaceutical's Depreciation & Amortization (CF) amounted to $18.5 million in Q3 2025, which was down 0.41% from $18.6 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's Depreciation & Amortization (CF)'s 5-year high stood at $28.0 million during Q1 2021, with a 5-year trough of $18.5 million in Q3 2025.
  • Its 3-year average for Depreciation & Amortization (CF) is $23.6 million, with a median of $25.4 million in 2023.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first increased by 9.40% in 2023, then fell by 29.85% in 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Depreciation & Amortization (CF) (Quarterly) stood at $26.0 million in 2021, then fell by 5.51% to $24.6 million in 2022, then increased by 9.40% to $26.9 million in 2023, then dropped by 12.11% to $23.6 million in 2024, then decreased by 2.73% to $18.5 million in 2025.
  • Its Depreciation & Amortization (CF) was $18.5 million in Q3 2025, compared to $18.6 million in Q2 2025 and $22.1 million in Q1 2025.